Health
Roche, BioNTech post ‘low’ response rate in cancer vaccine trial – FierceBiotech
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a “low” response rate. Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers po…
A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a low response rate. Nine of the 108 evaluable solid tumor patients responded when given the vacc…
Continue Reading